MaxCyte (MXCT) Set to Announce Quarterly Earnings on Tuesday

MaxCyte (NASDAQ:MXCT) is scheduled to release its earnings data after the market closes on Tuesday, May 7th. Analysts expect MaxCyte to post earnings of ($0.14) per share for the quarter. Parties that wish to register for the company’s conference call can do so using this link.

MaxCyte (NASDAQ:MXCT) last released its quarterly earnings data on Tuesday, March 12th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.05. The business had revenue of $15.67 million for the quarter, compared to analyst estimates of $15.60 million. MaxCyte had a negative return on equity of 15.90% and a negative net margin of 91.85%. On average, analysts expect MaxCyte to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

MaxCyte Trading Down 1.3 %

Shares of NASDAQ MXCT opened at $3.66 on Tuesday. The company has a market cap of $382.10 million, a price-to-earnings ratio of -9.89 and a beta of 1.34. MaxCyte has a 12 month low of $2.45 and a 12 month high of $5.55. The stock has a 50-day moving average price of $4.19 and a two-hundred day moving average price of $4.34.

Analyst Ratings Changes

MXCT has been the subject of a number of research analyst reports. Stephens reiterated an “overweight” rating and set a $11.00 price objective on shares of MaxCyte in a research report on Tuesday, April 23rd. William Blair reiterated an “outperform” rating on shares of MaxCyte in a report on Wednesday, March 13th. Finally, BTIG Research cut their price objective on MaxCyte from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Wednesday, March 13th.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.